Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64,725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, Yan Z, Cheng H, Chen W, Zhu F, Qi K, Li D, Sang W, Zhu L, Ma S, Li H, Zhang H, Qiu T, Yan D, Zhang Y, Peng S, Chang AH, Xu K, Li Z. Zhou D, et al. Among authors: chen w. Lancet Haematol. 2024 Oct;11(10):e751-e760. doi: 10.1016/S2352-3026(24)00176-5. Epub 2024 Jul 23. Lancet Haematol. 2024. PMID: 39059405 Clinical Trial.
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Qiao J, Yao R, Liu Y, Wang X, Zhang Y, Peng S, Huang CH, Zheng J, Li Z, Chang AH, Xu K. Xia J, et al. Among authors: chen w. J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881785 Free PMC article. Clinical Trial.
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, Cao J, Yan Z, Shi M, Cheng H, Zhu F, Sang W, Li D, Chen C, Xu K, Li Z. Liu Y, et al. Among authors: chen c, chen w. Front Immunol. 2023 Apr 19;14:1169071. doi: 10.3389/fimmu.2023.1169071. eCollection 2023. Front Immunol. 2023. PMID: 37153543 Free PMC article.
The prognostic significance of POD24 in peripheral T-cell lymphoma.
Chen H, Ma R, Zhang Q, Lu F, Ma Y, Zhou J, Cao J, Qi K, Yan Z, Sang W, Zhu F, Sun H, Li D, Li Z, Cheng H, Xu K, Chen W. Chen H, et al. Among authors: chen w. Hematology. 2024 Dec;29(1):2304483. doi: 10.1080/16078454.2024.2304483. Epub 2024 Jan 22. Hematology. 2024. PMID: 38251872 Free article.
Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.
Cheng H, Sun Y, Zhang X, Chen Z, Shao L, Liu J, Wang D, Chen Y, Wang X, Chen W, Sang W, Qi K, Li Z, Sun C, Shi M, Qiao J, Wu Q, Zeng L, Zheng J, Xu K, Cao J. Cheng H, et al. Among authors: chen z, chen w, chen y. Cytotherapy. 2024 Aug;26(8):832-841. doi: 10.1016/j.jcyt.2024.03.481. Epub 2024 Mar 29. Cytotherapy. 2024. PMID: 38625072
64,725 results
You have reached the last available page of results. Please see the User Guide for more information.